Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2023-08-15 Capital/Financing Update
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Trading Halt 2 pages 223.8KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Imugene Limited regarding a trading halt requested pending an announcement related to a proposed capital raising. It references ASX Listing Rule 17.1 and states the halt will remain until the announcement or a specified date. The document does not contain financial data, detailed report content, or results but is an announcement about a trading halt due to an upcoming capital raising announcement. This fits the category of Capital/Financing Update (CAP) as it relates to company fundraising activities and capital structure changes.
2023-08-15 English
Imugene Licenses Allogeneic CD19 CAR T Cell Therapy 5 pages 198.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Imugene Limited about licensing a new allogeneic CD19 CAR T cell therapy and plans to commence a registrational study in 2024. It details the licensing agreement terms, clinical trial data, and strategic plans. The content is focused on a corporate transaction and clinical development update rather than a financial report or earnings release. It is not a full annual or interim report, nor a call transcript or management discussion. The document is a formal announcement of a licensing and development deal, which fits best under Capital/Financing Update (CAP) as it involves acquisition of rights, payment terms, and strategic financing implications. The document length (9569 characters) and detailed content support this classification rather than a brief report publication announcement or regulatory filing. Therefore, the most appropriate classification is CAP with high confidence.
2023-08-15 English
Imugene VAXINIA Trial clears Cohort 3 of IT Monotherapy 3 pages 208.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited about the progress of a clinical trial (Phase 1 MAST trial) for their cancer therapy VAXINIA. It provides details on the trial cohort clearance, recruitment plans, and background on the trial and company. There are no financial statements, earnings data, or detailed financial analysis. The document is relatively short (4660 characters) and serves as a progress update rather than a full report. It is not a regulatory filing, earnings release, or management report. It is best classified as a general regulatory announcement about clinical trial progress, which fits under Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit other specific categories.
2023-08-13 English
Imugene CF33 Oncolytic Virus Study to be Showcased at SITC 2 pages 147.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about Imugene's CF33 Oncolytic Virus study being showcased at an upcoming scientific meeting (SITC Annual Meeting). It is a brief announcement describing the event and the company's participation, without any financial data, detailed report, or regulatory filing content. The document length is short (3476 characters), and it does not contain financial statements or detailed analysis. It is not a report itself but an announcement of an event related to the company. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-08-02 English
Imugene HER-Vaxx and CHECKVacc to be Featured at ESMO 2 pages 155.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited dated 24 July 2023. It announces that Imugene's immunotherapy platforms will be featured at the upcoming ESMO Congress. The content is promotional and informational about upcoming presentations and does not contain financial data, management changes, voting results, or regulatory filings. It is not a report, transcript, or detailed financial disclosure. The document is relatively short (3666 characters) and serves as a public announcement about participation in a medical congress. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-07-23 English
Quarterly Activities/Appendix 4C Cash Flow Report 15 pages 1.5MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities and Cash Flow Report' for the quarter ended 30 June 2023, issued by Imugene Limited. It includes detailed operational updates on clinical trials, FDA IND clearance, patent extension, board appointment, and financial cash flow data for the quarter. The presence of substantive financial data (cash flow report) and detailed business activities for a quarter indicates this is a comprehensive interim/quarterly report rather than a brief announcement or presentation. The document is about 15,000 characters long, which supports it being a full report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2023-07-20 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.